Non-invasive prenatal testing is a DNA test on maternal blood to screen pregnancies for the most common fetal chromosome anomalies such as trisomy 21 that is Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau syndrome. Whereas NIPT can also determine the gender of the fetus and NIPT is highly reliable in over 99% of Down syndrome cases. The results of the NIPT screening can help doctor to decide the next steps, including whether to have a diagnostic test like chorionic villus sampling (CVS) or collected from the amniotic fluid or placenta, to make sure whether a baby has a chromosome abnormality. Non-invasive prenatal testing can be performed any time after 9 weeks into your pregnancy earlier than any other prenatal screening or diagnostic test.

Download PDF Brochure Of This Report: https://www.coherentmarketinsights.com/insight/request-pdf/579

Rise in number of women choosing late pregnancies is expected to fuel the growth of non-invasive prenatal testing market
The average maternal age nowadays is increased due to rise in number of working women so the risk of pregnancies has also increased which shows the growth in the market of NIPT. As a woman age the risk of having baby with Down syndrome increase but other factor also play a role, which include the number of existing siblings and how big is the gap between the child and his immediate preceding sibling. As according to Centers for Disease Control and Prevention in year 2016, Down syndrome continues to be the most common chromosomal disorder, as each year about 6000 babies were born with Down syndrome in the U.S.
Whereas, Centers for Disease Control and Prevention also states in 2017 that older mothers are more likely to have a baby affected by Down syndrome than younger mothers. In other words, the prevalence of Down syndrome increases as the mother’s age increases, which is also expected to favor growth of non-invasive prenatal testing market.

Non-invasive Prenatal Testing Market Taxonomy:
By Product Type
• Assay Kits & Reagents
• Consumables
• Disposables
• Next-Generation Sequencing System
• Instruments
• PCR Instruments
• Ultrasound Devices
• Microarrays
• Other Instruments
By Method
• Ultrasound Detection
• Cell-free DNA in Maternal Plasma Tests
• Biochemical Screening tests
• Fetal Cells in Maternal Plasma Tests
By Application
• Trisomy
• Micro deletion Syndrome
• Other Application
By End User
• Diagnostic Laboratories
• Hospitals

Market Key Players Include:
GE Healthcare, Koninklijke Philips N.V., Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN N.V., Agilent Technologies, Inc., and Beijing Genomics Institute.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]